Nestle
Also known as: Galderma Laboratories, L.P. | Global Development Lead - GI care | Global Medical Affairs, Société des Produits Nestlé S.A., Vevey, Switzerland | Nestec Ltd. | Nestle | Nestlé | Nestle HealthCare Nutrition | Nestle Health Science | Nestle Health Science (China) Ltd. | Nestle Health Science, Medical Director | Nestlé Health Science Spain | Nestle Nutrition | Nestlé Portugal SA | NESTLE RESEARCH | Nestlé Research | Nestlé Research, Société des Produits Nestlé S.A., Lausanne, Switzerland | Purina Petcare | Société des Produits Nestlé S.A./CIL | Société des Produits Nestlé S.A./NIHS | Société des Produits Nestlé (SPN)
Highest phase reached
Phase 4
First clinical trial
Jun 1, 1995First marketed drug
Jul 21, 1980First NDA
Jul 21, 1980Last known activity
Jan 31, 2026
Timeline
1860s
- Jan 1, 1866
Nestle— Founded
1970s
- Jan 1, 1977
Alcon— Acquired
1990s
- Dec 28, 1990
tropicamide— Marketing Organization
2010s
- Aug 2, 2010
Vitaflo— Acquired
- Feb 2, 2011
CM&D Pharma— Acquired
- Feb 26, 2013
Pamlab— Acquired
- Apr 19, 2013
brimonidine— NDA Secondary Org
- Feb 11, 2014
Galderma— Acquired
- Dec 5, 2017
Atrium Innovations— Acquired
2020s
- Aug 31, 2020
Aimmune Therapeutics— Acquired
- Aug 12, 2024
nemolizumab— NDA Organization
Drugs by trial phase (250 distinct, 696 trials)
Phase 4 (3 own, 72 via acquisition)
Phase 3 (6 own, 30 via acquisition)
Phase 2 (2 own, 46 via acquisition)
Phase 1 (11 own, 3 via acquisition)
Other trials (56 own, 21 via acquisition)
Indications
Marketed drugs (50)
Subsidiaries (7 direct, 29 total across the full acquisition tree)
- Aimmune Therapeutics
- Alcon
- Atrium Innovations
- CM&D Pharma
- Galderma
- Pamlab
- Vitaflo
- AOV L2
- AquaCap L2
- Aurion Biotech L2
- CollaGenex Pharmaceuticals L2
- CooperVision Surgical L2
- Douglas Laboratories L2
- Endure Medical, Inc. L2
- Enzimas L2
- ESBATech AG L2
- LenSx Lasers L2
- Minami Nutrition Health L2
- Mucos Pharma GmbH and Co L2
- Optonol, Inc. L2
- Orthos Europe L2
- Owen dermatology company L2
- Q-Med AB L2
- Robert & Fils L2
- Spirig Pharma Ltd. L2
- Transcend Medical L2
- Trophic Canada L2
- WaveTec Vision L2
- Milex Products, Inc L3
Recent trials (50)
- NCT07296692CollaboratorN/AJan 31, 2026
- NCT07218640OfficialN/AOct 31, 2025
- NCT06953791CollaboratorPhase 2May 1, 2025
- NCT06593769Lead sponsorN/AOct 14, 2024
- NCT06593769OfficialN/AOct 14, 2024
- NCT05733364Lead sponsorN/AMar 8, 2023
- NCT05963594Lead sponsorN/AJan 23, 2023
- NCT05651529CollaboratorN/ADec 16, 2022
- NCT05364437CollaboratorN/AOct 4, 2022
- NCT05517122Lead sponsorN/AJun 27, 2022
- NCT05554991Lead sponsorN/AJun 24, 2022
- NCT05350566CollaboratorN/AJun 7, 2022
- NCT05459662Lead sponsorN/AMay 5, 2022
- NCT05054309Lead sponsorN/ANov 15, 2021
- NCT05349903CollaboratorN/ANov 10, 2021
Details
- Founded
- Cham, CH Jan 1, 1866
- First NDA
- Jul 21, 1980
- Last known activity
- Jan 31, 2026
Designations held
- Priority review
- Breakthrough therapy
Notes
--- Pre-folding founded info: 1866-06-01 Vevey CH https://en.wikipedia.org/wiki/Nestl%C3%A9 ---